Key result
Fimasartan 30 mg daily reduced mean 24-hour systolic blood pressure by 10.5 mmHg, showing comparable efficacy to the 5.5 mmHg reduction observed with valsartan 80 mg (p=0.1392).
Why the study?
Does fimasartan 30 mg daily reduce 24-hour systolic blood pressure compared to valsartan 80 mg daily in patients with mild to moderate essential hypertension?
RCT (n=75)
Double-blind
randomized
Yes
Does fimasartan 30 mg daily reduce 24-hour systolic blood pressure compared to valsartan 80 mg daily in patients with mild to moderate essential hypertension?
Low-dose fimasartan (30 mg) provides comparable 24-hour blood pressure lowering efficacy and tolerability to valsartan (80 mg) in patients with mild-to-moderate hypertension.
Answers are grounded in this paper and cite their sources.
Fimasartan 30 mg offers a comparable ARB option to valsartan for 24-hour SBP control; confirms class equivalence in this RCT.
BACKGROUND/AIMS: Fimasartan is an angiotensin type 1 receptor blocker (ARB) which has comparable efficacy and tolerability with other ARBs. The aim of this study was to evaluate 24-hour blood pressure (BP) lowering efficacy and the tolerability of the low dose fimasartan compared with valsartan in patients with mild to moderate hypertension. METHODS: This study was a phase II, prospective, multicenter, randomized, double-blind, parallel-grouped trial. A total of 75 hypertensive patients, whose mean ambulatory BP monitoring values were ≥ 135/85 mmHg, were randomized to either fimasartan 30 mg or valsartan 80 mg daily. The primary efficacy endpoint was the change in the mean 24-hour systolic BP (SBP) values from the baseline and at the week 8. Secondary endpoints included the change in the mean 24-hour diastolic BP values, the daytime and the nighttime mean BP values at week 8, the trough-to-peak (T/P) ratio and the smoothness index. RESULTS: At week 8, the mean 24-hour SBP values significantly decreased in both groups; -10.5 ± 11.9 mmHg (p < 0.0001) in the fimasartan group and -5.5 ± 11.6 mmHg (p = 0.0307) in the valsartan group. The difference between two groups was 4.3 ± 2.9 mmHg but there was no statistical significance (p = 0.1392). The global T/P ratio in the fimasartan 30 mg groups were 0.48 and 0.40 in the valsartan 80 mg group, respectively (p = 0.3411). The most frequent adverse events (AEs) were acute pharyngitis and there were no cases of severe AEs. CONCLUSIONS: In mild-to-moderate hypertensive patients, low dose (30 mg) fimasartan showed comparable 24-hour BP lowering efficacy compared with valsartan (80 mg). There was no difference in tolerability between two groups.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2017) conducted an RCT in mild to moderate essential hypertension (n=75). Fimasartan vs. Valsartan 80 mg daily was evaluated on change in the mean 24-hour systolic BP (SBP) values from the baseline at week 8 (MD 4.3, p=0.1392). Fimasartan 30 mg daily reduced mean 24-hour systolic blood pressure by 10.5 mmHg, showing comparable efficacy to the 5.5 mmHg reduction observed with valsartan 80 mg (p=0.1392).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: